Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T19:38:09.056Z.
Calculation as of: 2026-10-06T19:38:09.056Z.
Quote observation: 2026-10-06T19:35:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 033b533528001a3499036996a5838431eca9b2abd512acbebbb4929ff412c5bb
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$777.80M
EBITDA Yield
9.46%
TTM Avg
3.95%
3Y Avg
8.15%
5Y Avg
8.61%
Market Cap
$779.25M
EBITDA Yield
N/A
TTM Avg
7.18%
3Y Avg
23.84%
5Y Avg
23.84%
Market Cap
$781.24M
EBITDA Yield
15.10%
TTM Avg
18.56%
3Y Avg
15.22%
5Y Avg
13.39%
Market Cap
$763.14M
EBITDA Yield
5.45%
TTM Avg
6.26%
3Y Avg
5.92%
5Y Avg
4.44%
Market Cap
$787.11M
EBITDA Yield
N/A
TTM Avg
1.34%
3Y Avg
2.25%
5Y Avg
2.25%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | $772.26M | N/A | N/A | N/A | N/A |
| Varex Imaging Corporation (VREX)vs › | $777.80M | 9.46% | 3.95% | 8.15% | 8.61% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $761.20M | N/A | N/A | N/A | N/A |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $779.25M | N/A | 7.18% | 23.84% | 23.84% |
| Geron Corporation (GERN)vs › | $779.45M | N/A | 0.13% | 0.13% | 0.13% |
| AdaptHealth Corp. (AHCO)vs › | $781.24M | 15.10% | 18.56% | 15.22% | 13.39% |
| Mesa Laboratories, Inc. (MLAB)vs › | $763.14M | 5.45% | 6.26% | 5.92% | 4.44% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $787.11M | N/A | 1.34% | 2.25% | 2.25% |
| InMode Ltd. (INMD)vs › | $802.64M | 17.01% | 14.19% | 12.45% | 9.40% |
| Jade Biosciences, Inc. (JBIO)vs › | $802.74M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
